References
- Mrowietz U, Barker J, Boehncke WH, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a european expert consensus. J Eur Acad Dermatol Venereol. 2018;32(3):3–14.
- Augustin M, Enk A, von Kiedrowski R, et al. Einsatz von systemtherapeutika und biologika in der leitliniengerechten therapie der mittelschweren bis schweren psoriasis vulgaris. PsoNet Magazin. 2017;4(Suppl. 1):1–28.
- Mrowietz U, Morrison PJ, Suhrkamp I, et al. The pharmacokinetics of fumaric acid esters reveal their in vivo effects. Trends Pharmacol Sci. 2018;39(1):1–12.
- Mrowietz U, Szepietowski JC, Loewe R, et al. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, fumaderm®- and placebo-controlled trial (BRIDGE). Br J Dermatol. 2017;176(3):615–623.
- European Medicines Agency [Internet]. EPAR summary for the public: skilarence. Dimethyl fumarate. Amsterdam (The Netherlands): European Medicines Agency; 2017 [cited 2021 Jun 17]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002157/WC500231110.pdf
- Reich K, Pinter A, Leutz A, et al. A 24-week, randomised, open-label comparison of ixekizumab versus fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic therapy. Paper presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress; 2017 September 12–17; Geneva, Switzerland.
- Walker F, Adamczyk A, Kellerer C, et al. Fumaderm® in daily practice for psoriasis: dosing, efficacy and quality of life. Br J Dermatol. 2014;171(5):1197–1205.
- Nast A, Amelunxen L, Augustin M, et al. S3 guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. J Dtsch Dermatol Ges. 2018;16(5):645–669.
- Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
- Almirall Limited [Internet]. Skilarence 30 mg gastro-resistant tablets. Summary of product characteristics. Barcelona (Spain): Almirall Limited; 2020 [cited 2021 Jun 17]. ]. Available from: https://www.medicines.org.uk/emc/product/752/smpc